A141080 Stock Overview
A clinical stage biopharmaceutical company, engages in the discovery and development of medicines for unmet medical needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
LigaChem Biosciences Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩110,900.00 |
| 52 Week High | ₩143,600.00 |
| 52 Week Low | ₩58,800.00 |
| Beta | 1.27 |
| 1 Month Change | 7.36% |
| 3 Month Change | -6.10% |
| 1 Year Change | 74.92% |
| 3 Year Change | 154.94% |
| 5 Year Change | 327.36% |
| Change since IPO | 1,167.43% |
Recent News & Updates
LigaChem Biosciences' (KOSDAQ:141080) Earnings Are Weaker Than They Seem
Mar 29
LigaChem Biosciences Inc.'s (KOSDAQ:141080) Share Price Could Signal Some Risk
Mar 20Recent updates
LigaChem Biosciences' (KOSDAQ:141080) Earnings Are Weaker Than They Seem
Mar 29LigaChem Biosciences Inc.'s (KOSDAQ:141080) Share Price Could Signal Some Risk
Mar 20LigaChem Biosciences (KOSDAQ:141080) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Dec 21Risks Still Elevated At These Prices As LigaChem Biosciences Inc. (KOSDAQ:141080) Shares Dive 26%
Nov 29LigaChem Biosciences (KOSDAQ:141080) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Sep 09Here's Why LigaChem Biosciences (KOSDAQ:141080) Can Manage Its Debt Despite Losing Money
May 23A Look At The Fair Value Of LegoChem Biosciences, Inc. (KOSDAQ:141080)
Mar 29What Kind Of Shareholders Hold The Majority In LegoChem Biosciences, Inc.'s (KOSDAQ:141080) Shares?
Jan 28Estimating The Fair Value Of LegoChem Biosciences, Inc. (KOSDAQ:141080)
Dec 07
Shareholder Returns
| A141080 | KR Life Sciences | KR Market | |
|---|---|---|---|
| 7D | 23.9% | -0.08% | -1.0% |
| 1Y | 74.9% | 37.1% | -11.5% |
Return vs Industry: A141080 exceeded the KR Life Sciences industry which returned 37.1% over the past year.
Return vs Market: A141080 exceeded the KR Market which returned -11.5% over the past year.
Price Volatility
| A141080 volatility | |
|---|---|
| A141080 Average Weekly Movement | 7.5% |
| Life Sciences Industry Average Movement | 5.4% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in KR Market | 12.5% |
| 10% least volatile stocks in KR Market | 2.8% |
Stable Share Price: A141080 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A141080's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 163 | Yong Kim | ligachembio.com |
LigaChem Biosciences Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of medicines for unmet medical needs. The company researches and develops products for various therapeutic areas, including antibiotics, anti-fibrotics, immuno-oncology, oncology; and antibody-drug conjugate (ADC) platform technology and small molecule drugs. It also sells medical device and supplies.
LigaChem Biosciences Inc. Fundamentals Summary
| A141080 fundamental statistics | |
|---|---|
| Market cap | ₩3.91t |
| Earnings (TTM) | ₩7.80b |
| Revenue (TTM) | ₩125.90b |
515.8x
P/E Ratio32.0x
P/S RatioIs A141080 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A141080 income statement (TTM) | |
|---|---|
| Revenue | ₩125.90b |
| Cost of Revenue | ₩15.95b |
| Gross Profit | ₩109.95b |
| Other Expenses | ₩102.15b |
| Earnings | ₩7.80b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 214.99 |
| Gross Margin | 87.33% |
| Net Profit Margin | 6.20% |
| Debt/Equity Ratio | 0% |
How did A141080 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/14 10:54 |
| End of Day Share Price | 2025/04/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
LigaChem Biosciences Inc. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mujinn Lee | Cape Investment & Securities Co., Ltd. |
| Seohyun Lee | Citigroup Inc |
| Citi Research | Citigroup Inc |